Quantcast
Last updated on April 18, 2014 at 0:14 EDT

Latest Nuvelo Stories

2014-01-30 16:26:49

DUBLIN, January 30, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/sxtcgx/cancer_diagnostic) has announced the addition of the "Cancer Diagnostic Testing World Markets" [http://www.researchandmarkets.com/research/sxtcgx/cancer_diagnostic ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Cancer testing is one of the most important growth opportunities for the next three to five years in...

2013-08-19 08:28:09

RnRMarketResearch.com adds Cancer Diagnostics Market 2013 Sales Forecasts, Supplier Shares, Competitive Strategies reports for US, UK, Spain, Japan, Italy, Germany and France. DALLAS, Aug. 19, 2013 /PRNewswire-iReach/ -- These comprehensive cancer diagnostics market research reports examine trends for the diagnostics market in US, UK, Spain, Japan, Italy, Germany and France including reviews of current and emerging tests, analysis of potential applications of various diagnostic...

2013-04-30 16:30:02

INCLINE VILLAGE, Nev., April 30, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has appointed Peter S. Garcia to the position of vice president, chief financial officer (CFO) and acting chief accounting officer, effective as of May 13, 2013. Mr. Garcia has spent the last 16 years in various CFO positions for biotechnology companies. He joins PDL from BioTime, Inc. (NYSE MKT: BTX) where he served as CFO since 2011. (Logo:...

2012-09-07 02:23:46

SAN DIEGO, Sept. 7, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) today announced that Ted W. Love, M.D., has joined its Board of Directors. Dr. Love most recently served as Executive Vice President and Head of Research and Development and Technical Operations at Onyx Pharmaceuticals, Inc., where he launched four multi-center, global phase 3 studies in two years and played a key role in obtaining in 2012 accelerated approval from the FDA to market Kyprolis(TM)...

2012-08-16 02:24:17

SAN MATEO, Calif., Aug. 16, 2012 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced that Richard B. Brewer, 61, its Executive Chairman of the Board, has died after a long and courageous battle with multiple myeloma, a type of blood cancer. "Dick embodied the bold creativity and passion for patients that make the biotechnology industry so great. His leadership for 35 years was marked...

2011-10-18 16:37:00

BOULDER, Colo., Oct. 18, 2011 /PRNewswire/ -- SomaLogic, Inc., announced today that it has entered into a multi-year research agreement with Novartis to use its unique proprietary proteomics technology to accelerate Novartis' drug discovery and development efforts. "We are excited by this opportunity to work with Novartis' world-class researchers to help them define robust biomarkers, validate novel drug targets, and even develop companion clinical diagnostics," said Larry Gold, CEO of...

2010-12-21 08:00:00

ALBUQUERQUE, N.M., Dec. 21, 2010 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty diagnostics laboratory that discovers, develops and markets proprietary tests, today announced that it has been awarded $400,000 in funding under the IRS Qualifying Therapeutic Discovery Project (QTDP) program, which was created by Congress as part of the Patient Protection and Affordable Care Act of 2010. Proceeds from the grants will be used to advance the development of biomarker studies underway,...

2010-09-22 10:15:00

NEW YORK, Sept. 22 /PRNewswire/ -- Signal Genetics, a privately held predictive genetic testing company focused on oncology, today announced the company will work with Array BioPharma to help push forward both companies' goals of markers for patient selection, helping bring personalized medicine and companion diagnostics to patients with multiple myeloma, a cancer of the bone marrow and antibody producing cells. Signal Genetics' groundbreaking MyPRS(TM) genomic testing platform will be...

2010-03-17 06:30:00

SAN DIEGO, March 17 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially...

2010-02-01 10:15:00

EMERYVILLE, Calif., Feb. 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it has appointed Ted W. Love, M.D., Executive Vice President and Head of Research and Development. In addition, Michael Kauffman, M.D., Ph.D., who has served as Interim Chief Medical Officer since November 2009, has been appointed Chief Medical Officer reporting to Dr. Love. In his new role, Dr. Love will report to the Chief Executive Officer and will be responsible for...